Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102589 | 0.85 | EGFR (0.74) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL11001723 | 0.85 | EGFR (0.74) | EGFRALDH1A1GAAHPGDRAB9A | |
| SCHEMBL14422913 | 0.84 | EGFR (0.72) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL11001168 | 0.84 | EGFR (0.72) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL11004123 | 0.83 | EGFR (0.70) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL4104287 | 0.83 | EGFR (0.70) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL11017752 | 0.82 | EGFR (0.69) | EGFRGAAHPGDRAB9ANPC1 | |
| SCHEMBL11158107 | 0.81 | EGFR (0.69) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL14422912 | 0.81 | EGFR (0.68) | EGFRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL2951112 | 0.81 | RAB9A (0.77) | EGFRRAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERK PATENT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1531817-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004019941-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | ARAF, BRAF, RAF1 | EGFR 115/4885ALDH1A1 1285/4885GAA 318/4885 |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | BRAF, RAF1, ARAF | EGFR 319/4885ALDH1A1 2318/4885GAA 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.